Cholera (cholera), a virulent intestinal infection caused by Vibrio cholerae, has a rapid onset and spreads quickly, and is an important cause of diarrhea in most parts of Asia and Africa, and is an international quarantine infection. Fingerprints wrinkled prevention methods: to improve the immunity of the population In the past, the application of the whole bacteria dead vaccine or and cholera enterotoxin toxoid vaccine immunization of the population, due to low protection rate, short protection time, and can not prevent hidden infection and carriers, and therefore no longer advocate the application. At present, foreign genetic engineering technology and trial of a variety of vaccines, is still expanding the trial, including: 1, B subunit – whole bacterium vaccine (BS-WC): this is the inactivation of Vibrio cholerae whole bacterium cells (WC) and purified cholera enterotoxin B subunit (BS) composed of vaccines. The cell wall of WC contains antigens such as lipopolysaccharide (LPS) and cholera toxin synergist hair (TCP), which can induce the body to produce antibacterial antibodies and thus inhibit the settlement of Vibrio cholerae in the intestine; while the antiviral antibodies produced by BS can neutralize the B subunit of CT, so that the cholera enterotoxin cannot bind to the intestinal mucosal receptors and has no way to exert enterotoxic effects. This vaccine protection rate of 65% to 85%, the prevention of classical biotype Vibrio cholerae is better than Elto biotype Vibrio cholerae. 2, attenuated oral live vaccine (CVDl03-HgR): This is the application of DNA recombinant technology to remove 94% of the CTXA gene, recombinant in the classical biotype Vibrio cholerae strain 569B, to obtain attenuated strain CVD103, and then introduced a gene encoding the resistance to mercury (Hg) into the chromosomal locus of hgla, become CVD103-HgR attenuated strain. This vaccine was significantly resistant to infection by group O1 classical biotype and Elto biotype Vibrio cholerae. taket et al. reported that 100% protection was obtained in volunteers after oral administration of (3-5) × 108. single dose of CVD103-HgR bacteria. The protective effect is generally considered to last for at least 6 months. However, animal experiments have shown that this vaccine has no protective effect against Vibrio cholerae type O139. Woldol- et al. had constructed VCO139 attenuated strain Bengal3 that lacked cytotoxin (CT) and adenylyl cyclase (ACE) zot and other toxins, but its safety and protective power etc. need to be further studied. 3, O139 vaccine research: O139 podocyte lipopolysaccharide is not only an important virulence factor, but also an important protective antigen, serum protein as a carrier protein to make O139 podocyte lipopolysaccharide vaccine, the application of EDC or CDAP as the activating factor injected into mice, can make mice produce antibodies to kill Vibrio. Also, covalent binding of O139 podolipoprotein to diphtheria toxin can cause mice to produce IgG against podolipoprotein, which has a vibrio-killing effect, and also produce antibodies against diphtheria toxin, and this study is still in the animal experimental stage.